INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare

Event · Earnings
Also in this documentGuidance · reaffirm

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 3, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INNV
Bullish
high confidence
Mentioned
$INNV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INNVBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to trigger buying interest, especially from investors focused on government‑payor healthcare models.

02

Market read

First‑report earnings and guidance for a mid‑cap healthcare firm; material new data for traders.

03

What to watch

Potential risks from Medicaid reimbursement changes or higher debt servicing costs not fully disclosed.

Relevance 7/10Novelty 8/10Timing: after‑hours today
AlphAI · Earnings readINNV · Fiscal first quarter 2027 · ended September 30, 2026

InnovAge reported fiscal first-quarter 2027 total revenues of $264,757 (in thousands), net income of $20,878 (in thousands), and Adjusted EBITDA of $31,251 (in thousands), while confirming fiscal year 2027 guidance.

✓Strong quarter

Revenue increased approximately 12.1%, income before income taxes increased approximately 153.1%, Center-level Contribution Margin increased 23.8%, and Adjusted EBITDA increased by $13.6 million. Margins expanded across income before income taxes, net income, Center-level Contribution Margin, and Adjusted EBITDA.

Revenue
$265M
approximately 12.1% y/y
PACE
$265M
EPS · GAAP
$0.14
Fiscal year 2027 outlook
$1,050 to $1,085 (dollars in millions)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$264.8M–approximately 12.1%
Capitation revenue, three months ended September 30, 2026GAAP$264.7M––
Other service revenue, three months ended September 30, 2026GAAP$67K––
External provider costs, three months ended September 30, 2026GAAP$115.7M––
Cost of care, excluding depreciation and amortization, three months ended September 30, 2026GAAP$85.50M––
Sales and marketing expense, three months ended September 30, 2026GAAP$8.63M––
Corporate, general and administrative expense, three months ended September 30, 2026GAAP$29.15M––
Depreciation and amortization, three months ended September 30, 2026GAAP$5.66M––
Total expenses, three months ended September 30, 2026GAAP$244.6M––
Operating Income, three months ended September 30, 2026GAAP$20.15M––
Interest expense, net, three months ended September 30, 2026GAAP−$123K––
Other income, net, three months ended September 30, 2026GAAP$10K––
Income Before Income Taxes, three months ended September 30, 2026GAAP$20.04M–approximately 153.1%
Income Before Income Taxes as a percent of revenue, three months ended September 30, 2026GAAP7.6%–an increase of 4.2 percentage points
Provision (Benefit) for Income Taxes, three months ended September 30, 2026GAAP−$841K––
Net Income, three months ended September 30, 2026GAAP$20.88M––
Net Income margin, three months ended September 30, 2026GAAP7.9%–an increase of 4.6 percentage points
Net Income Attributable to InnovAge Holding Corp., three months ended September 30, 2026GAAP$19.55M––
Net loss per share - basic, three months ended September 30, 2026GAAP$0.14––
Net loss per share - diluted, three months ended September 30, 2026GAAP$0.14––
Center-level Contribution Margin, three months ended September 30, 2026non-GAAP$63.59M–23.8%
Center-level Contribution Margin as a % of revenue, three months ended September 30, 2026non-GAAP24.0%–an increase of 2.2 percentage points
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$31.25M–an increase of $13.6 million
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP11.8%–an increase of 4.3 percentage points
Census, fiscal first quarter 2027otherapproximately 8,420 participants––
Member months, fiscal first quarter 2027otherapproximately 25,070––
Net cash provided by operating activities, three months ended September 30, 2026GAAP$28.74M––
Net cash used in investing activities, three months ended September 30, 2026GAAP−$3.42M––
Purchases of property and equipment, three months ended September 30, 2026GAAP−$2.99M––
Net cash used in financing activities, three months ended September 30, 2026GAAP−$3.96M––
Cash and cash equivalents as of September 30, 2026GAAP$119.3M––
Short-term investments as of September 30, 2026GAAP$43.74M––
Debt on the balance sheet at the end of fiscal first quarter 2027GAAP$61.4M––

Segments

SegmentRevenueq/qy/y
PACEPACE capitation revenue was $264,690 (in thousands).$264.8M––
All otherThe prior-year all other revenue was $257 (in thousands), primarily attributable to the Senior Housing operating segment, whose assets were sold on September 11, 2025.$— (in thousands)––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Fiscal year 2027 outlook

  • Revenue$1,050 to $1,085 (dollars in millions)
  • NoteCensus: 8,625 to 8,850
  • NoteTotal Member Months: 101,000 to 102,500
  • NoteAdjusted EBITDA: $105 to $115 (dollars in millions, non-GAAP)

What drove it

  • Continued census growth and disciplined clinical and operational execution were cited as drivers of financial performance.
  • Census was approximately 8,420 participants, compared with 7,890 participants in the first quarter of fiscal year 2026.
  • Member months were approximately 25,070, compared with 23,500 in the first quarter of fiscal year 2026.
  • Center-level Contribution Margin increased 23.8% to $63,587 (in thousands), and its margin increased 2.2 percentage points to 24.0%.
  • Corporate, general and administrative expense was $29,149 (in thousands), compared with $30,273 (in thousands).
  • Interest expense, net was $(123) (in thousands), compared with $(1,251) (in thousands).

Concerns

  • The Company stated that expected results and estimates may be impacted by factors outside its control and actual results may be materially different from guidance.
  • Business optimization expense was $1,707 (in thousands), including $1.5 million related to organizational restructure and executive severance and $0.2 million related to closure of the previously planned de novo center in Downey, California.
  • Offering expenses were $1,679 (in thousands) related to filing and legal fees for the Form S-3 Shelf Registration Statement and subsequent secondary offering.
  • The forward-looking statement disclosures identify risks including reductions in PACE reimbursement rates, Medicaid budget reductions, healthcare cost inflation, labor shortages, and government-program reviews, audits and investigations.

What to watch

  • Progress toward fiscal year 2027 census guidance of 8,625 to 8,850 and Total Member Months guidance of 101,000 to 102,500.
  • Execution against fiscal year 2027 total revenues guidance of $1,050 to $1,085 and Adjusted EBITDA guidance of $105 to $115.
  • Whether Center-level Contribution Margin and Adjusted EBITDA margins sustain the fiscal first-quarter levels of 24.0% and 11.8%, respectively.
  • Cash generation following $28,742 (in thousands) of net cash provided by operating activities in the fiscal first quarter.
  • The effect of business optimization, organizational restructure and executive severance costs, and costs related to the Downey, California center closure.

Balance sheet and cash flow

  • Cash and cash equivalents were $119,253 (in thousands) as of September 30, 2026, compared with $97,891 (in thousands) as of June 30, 2026.
  • Short-term investments were $43,740 (in thousands) as of September 30, 2026, compared with $43,435 (in thousands) as of June 30, 2026.
  • The Company reported $61.4 million in debt, representing debt under its senior secured term loan, revolving credit facility and finance lease obligations.
  • Net cash provided by operating activities was $28,742 (in thousands), compared with $3,924 (in thousands).
  • Net cash used in investing activities was $(3,425) (in thousands), including purchases of property and equipment of $(2,988) (in thousands).
  • Net cash used in financing activities was $(3,956) (in thousands).

Analysis

InnovAge began fiscal 2027 with $264,757 (in thousands) of total revenues, compared with $236,105 (in thousands) in the fiscal first quarter of 2026. The Company characterized the increase as approximately 12.1%. Census rose to approximately 8,420 participants from 7,890 participants, while member months rose to approximately 25,070 from 23,500. Capitation revenue was $264,690 (in thousands), comprising nearly all reported revenue.

Profitability increased materially. Income Before Income Taxes was $20,037 (in thousands), compared with $7,916 (in thousands), an approximately 153.1% increase. Its percentage of revenue was 7.6%, up 4.2 percentage points from 3.4%. Net Income was $20,878 (in thousands), compared with $7,669 (in thousands), and Net Income margin was 7.9%, up 4.6 percentage points. Net Income Attributable to InnovAge Holding Corp. was $19,553 (in thousands), or $0.14 per basic and diluted share, compared with $8,019 (in thousands), or $0.06 per share.

Non-GAAP operating measures also strengthened. Center-level Contribution Margin was $63,587 (in thousands), up 23.8% from $51,356 (in thousands), and its margin reached 24.0% from 21.8%. Adjusted EBITDA was $31,251 (in thousands), compared with $17,642 (in thousands), while Adjusted EBITDA margin increased to 11.8% from 7.5%. Corporate, general and administrative expense declined to $29,149 (in thousands) from $30,273 (in thousands), although the quarter included $1,707 (in thousands) of business optimization expense and $1,679 (in thousands) of offering expenses in the Adjusted EBITDA reconciliation.

Cash generation improved, with net cash provided by operating activities of $28,742 (in thousands), compared with $3,924 (in thousands). Cash and cash equivalents were $119,253 (in thousands) and short-term investments were $43,740 (in thousands) at September 30, 2026. InnovAge confirmed fiscal year 2027 guidance, including total revenues of $1,050 to $1,085 and Adjusted EBITDA of $105 to $115, both stated in dollars in millions. Management said that, effective in fiscal year 2027, prepared remarks will emphasize year-over-year performance rather than previously reported sequential-quarter comparisons.

Management, verbatim

We are pleased with our strong stat to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance.

Patrick Blair, Chief Executive Officer of InnovAge

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Free cash flow was not reported.
  • Share repurchases and dividends were not reported.
  • Guidance for gross margin, operating expenses and tax rate was not provided.
  • Quarterly sequential comparisons were not reported in the financial-results discussion.
  • Formal reportable-segment operating income was not reported.
  • The previous outlook covered the full fiscal year 2027 only, and this release reports the first quarter, so there is nothing to compare for this period.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The filing is the first public disclosure of InnovAge's Q1 performance and FY2027 outlook, released via SEC Form 8‑K and a GlobeNewswire press release.

Company-level read

Ticker impact

$INNVBullishHigh confidence
Context

InnovAge Holding Corp. filed an 8‑K reporting Q1 2026 results and FY2027 guidance, revealing 12% revenue growth and double‑digit earnings improvement.

Expected impact

upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Revenue and net income jumped significantly year‑over‑year and FY guidance exceeds prior expectations, suggesting better cash flow and growth prospects.

Market effects

Positive for the PACE/elder‑care sector, may boost peers with similar government‑payor exposure.

Limited to U.S. healthcare investors; no broader regional effect.

Modest, confined to U.S. small‑cap healthcare space.

Counterpoint

If guidance falls short of analyst consensus, the stock could face disappointment despite headline growth.

Key entities

  • InnovAge Holding Corp.

    NASDAQ‑listed provider of PACE senior‑care programs.

  • Patrick Blair

    CEO of InnovAge who commented on the results.

Every INNV earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$INNVMed

InnovAge settles DOJ civil claims for $37 million

InnovAge Holding Corp. (INNV) settled civil claims with the DOJ for $37 million, covering alleged conduct from 2016 to 2022. The company did not admit wrongdoing. InnovAge provides senior healthcare programs and has invested in compliance and operations. As of September 2026, it served 8,420 participants across 20 centers in six states.

$INNVMed

InnovAge (INNV) Q1 2027 Earnings Call Transcript

InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.

$INNVMed

What InnovAge (INNV) Said on Its Q1 Earnings Call

InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.